Enhancing FTS (Salirasib) efficiency via combinatorial treatment
Identifieur interne : 000F58 ( Main/Exploration ); précédent : 000F57; suivant : 000F59Enhancing FTS (Salirasib) efficiency via combinatorial treatment
Auteurs : Eya Wolfson [Israël] ; Eran Schmukler [Israël] ; Sari Trangle Schokoroy [Israël] ; Yoel Kloog [Israël] ; Ronit Pinkas-Kramarski [Israël]Source :
- Biology of the Cell [ 0248-4900 ] ; 2015-05.
Abstract
The Ras oncogene transmits signals, which regulate various cellular processes including cell motility, differentiation, growth and death. Since Ras signalling is abnormally activated in more than 30% of human cancers, Ras and its downstream signalling pathways are considered good targets for therapeutic interference. Ras is post‐translationally modified by the addition of a farnesyl group, which permits its attachment to the plasma membrane. Exploiting this knowledge, a synthetic Ras inhibitor, S‐trans, trans‐farnesylthiosalicylic acid (FTS; Salirasib), was developed. FTS resembles the farnesylcysteine group of Ras, and acts as an effective Ras antagonist. In the present review, the effect of FTS in combination with various other drugs, as tested in vitro and in vivo, and its therapeutic potential are discussed. As reviewed, FTS cooperates with diverse therapeutic agents, which significantly improves treatment outcome. Therefore, combinations of FTS with other agents have a potential to serve as anti‐cancer or anti‐inflammatory therapies.
The small G‐protein Ras transmits signals regulating proliferation and is activated in more than 30% of human cancers. The present review describes studies on the effects of the synthetic Ras inhibitor, S‐trans, trans‐farnesylthiosalicylic acid (FTS), in combination with various other drugs and the therapeutic potential of these combined treatments. As discussed, combinations of FTS with other agents are significantly more effective and therefore have a therapeutic potential.
Url:
DOI: 10.1111/boc.201400087
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001E19
- to stream Istex, to step Curation: 001E19
- to stream Istex, to step Checkpoint: 000103
- to stream Main, to step Merge: 000F59
- to stream Main, to step Curation: 000F58
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Enhancing FTS (Salirasib) efficiency via combinatorial treatment</title><author><name sortKey="Wolfson, Eya" sort="Wolfson, Eya" uniqKey="Wolfson E" first="Eya" last="Wolfson">Eya Wolfson</name></author><author><name sortKey="Schmukler, Eran" sort="Schmukler, Eran" uniqKey="Schmukler E" first="Eran" last="Schmukler">Eran Schmukler</name></author><author><name sortKey="Schokoroy, Sari Trangle" sort="Schokoroy, Sari Trangle" uniqKey="Schokoroy S" first="Sari Trangle" last="Schokoroy">Sari Trangle Schokoroy</name></author><author><name sortKey="Kloog, Yoel" sort="Kloog, Yoel" uniqKey="Kloog Y" first="Yoel" last="Kloog">Yoel Kloog</name></author><author><name sortKey="Pinkas Ramarski, Ronit" sort="Pinkas Ramarski, Ronit" uniqKey="Pinkas Ramarski R" first="Ronit" last="Pinkas-Kramarski">Ronit Pinkas-Kramarski</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B50C4E273200D347EBD16F52B4E51BE2B1EDC0A6</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1111/boc.201400087</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-LPDF57MV-B/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001E19</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001E19</idno><idno type="wicri:Area/Istex/Curation">001E19</idno><idno type="wicri:Area/Istex/Checkpoint">000103</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000103</idno><idno type="wicri:doubleKey">0248-4900:2015:Wolfson E:enhancing:fts:salirasib</idno><idno type="wicri:Area/Main/Merge">000F59</idno><idno type="wicri:Area/Main/Curation">000F58</idno><idno type="wicri:Area/Main/Exploration">000F58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Enhancing FTS (Salirasib) efficiency via combinatorial treatment</title><author><name sortKey="Wolfson, Eya" sort="Wolfson, Eya" uniqKey="Wolfson E" first="Eya" last="Wolfson">Eya Wolfson</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurobiology, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Schmukler, Eran" sort="Schmukler, Eran" uniqKey="Schmukler E" first="Eran" last="Schmukler">Eran Schmukler</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurobiology, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Schokoroy, Sari Trangle" sort="Schokoroy, Sari Trangle" uniqKey="Schokoroy S" first="Sari Trangle" last="Schokoroy">Sari Trangle Schokoroy</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurobiology, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Kloog, Yoel" sort="Kloog, Yoel" uniqKey="Kloog Y" first="Yoel" last="Kloog">Yoel Kloog</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurobiology, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Pinkas Ramarski, Ronit" sort="Pinkas Ramarski, Ronit" uniqKey="Pinkas Ramarski R" first="Ronit" last="Pinkas-Kramarski">Ronit Pinkas-Kramarski</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurobiology, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Israël</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Biology of the Cell</title><title level="j" type="alt">BIOLOGY OF THE CELL</title><idno type="ISSN">0248-4900</idno><idno type="eISSN">1768-322X</idno><imprint><biblScope unit="vol">107</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="130">130</biblScope><biblScope unit="page" to="143">143</biblScope><biblScope unit="page-count">14</biblScope><date type="published" when="2015-05">2015-05</date></imprint><idno type="ISSN">0248-4900</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0248-4900</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">The Ras oncogene transmits signals, which regulate various cellular processes including cell motility, differentiation, growth and death. Since Ras signalling is abnormally activated in more than 30% of human cancers, Ras and its downstream signalling pathways are considered good targets for therapeutic interference. Ras is post‐translationally modified by the addition of a farnesyl group, which permits its attachment to the plasma membrane. Exploiting this knowledge, a synthetic Ras inhibitor, S‐trans, trans‐farnesylthiosalicylic acid (FTS; Salirasib), was developed. FTS resembles the farnesylcysteine group of Ras, and acts as an effective Ras antagonist. In the present review, the effect of FTS in combination with various other drugs, as tested in vitro and in vivo, and its therapeutic potential are discussed. As reviewed, FTS cooperates with diverse therapeutic agents, which significantly improves treatment outcome. Therefore, combinations of FTS with other agents have a potential to serve as anti‐cancer or anti‐inflammatory therapies.</div><div type="abstract" xml:lang="en">The small G‐protein Ras transmits signals regulating proliferation and is activated in more than 30% of human cancers. The present review describes studies on the effects of the synthetic Ras inhibitor, S‐trans, trans‐farnesylthiosalicylic acid (FTS), in combination with various other drugs and the therapeutic potential of these combined treatments. As discussed, combinations of FTS with other agents are significantly more effective and therefore have a therapeutic potential.</div></front></TEI><affiliations><list><country><li>Israël</li></country></list><tree><country name="Israël"><noRegion><name sortKey="Wolfson, Eya" sort="Wolfson, Eya" uniqKey="Wolfson E" first="Eya" last="Wolfson">Eya Wolfson</name></noRegion><name sortKey="Kloog, Yoel" sort="Kloog, Yoel" uniqKey="Kloog Y" first="Yoel" last="Kloog">Yoel Kloog</name><name sortKey="Pinkas Ramarski, Ronit" sort="Pinkas Ramarski, Ronit" uniqKey="Pinkas Ramarski R" first="Ronit" last="Pinkas-Kramarski">Ronit Pinkas-Kramarski</name><name sortKey="Pinkas Ramarski, Ronit" sort="Pinkas Ramarski, Ronit" uniqKey="Pinkas Ramarski R" first="Ronit" last="Pinkas-Kramarski">Ronit Pinkas-Kramarski</name><name sortKey="Schmukler, Eran" sort="Schmukler, Eran" uniqKey="Schmukler E" first="Eran" last="Schmukler">Eran Schmukler</name><name sortKey="Schokoroy, Sari Trangle" sort="Schokoroy, Sari Trangle" uniqKey="Schokoroy S" first="Sari Trangle" last="Schokoroy">Sari Trangle Schokoroy</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B50C4E273200D347EBD16F52B4E51BE2B1EDC0A6
|texte= Enhancing FTS (Salirasib) efficiency via combinatorial treatment
}}
| This area was generated with Dilib version V0.6.33. |  |